Lv2
136 积分 2026-04-28 加入
<i>HER2</i>-Altered NSCLC: Exploring New Therapies and Making Treatment Decisions
4个月前
已关闭
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
4个月前
已完结
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
4个月前
已完结
Abstract CT301: SHR-A1811 ± adebrelimab as first-line (1L) treatment for advanced HER2-mutant NSCLC: A randomized phase 2 cohort from a phase 1b/2 study
4个月前
已完结
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
4个月前
已完结
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
4个月前
已完结
[Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)]
4个月前
已完结
[Expert consensus on diagnosis and treatment of advanced non-small cell lung cancer with HER-2 alterations (2025 edition)]
4个月前
已完结
Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
5个月前
已完结
A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs
5个月前
已完结
皖公网安备34019202002308
